TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34547270

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 1:200000 epinephrine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 28
Study: 34532749

Group type: EXPERIMENTAL
Intervention: Guanxin Danshen Dropping Pill (0.4 g, thrice daily) and Andrographis tablet (0.2 g, thrice daily) for 4 weeks
Number of subjects: 154

Group type: COMPARATOR
Intervention: Guanxin Danshen Dropping Pill (0.4 g, thrice daily)
Number of subjects: 154
Study: 35019665

Group type: EXPERIMENTAL
Intervention: Alloplastic bone grafts at third molar extraction sites
Number of subjects: 27

Group type: COMPARATOR
Intervention: Nongrafted sites
Number of subjects: 27
Study: 32196856

Group type: EXPERIMENTAL
Intervention: Intramuscular hyosine n-butyl bromide (HBB) 40 mg (2 mL)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo (2 mL of water for injection)
Number of subjects: 124
Study: 35593966

Group type: EXPERIMENTAL
Intervention: REThink therapeutic game
Number of subjects: 142

Group type: COMPARATOR
Intervention: Standard face‐to‐face prevention program
Number of subjects: 142

Group type: COMPARATOR
Intervention: Waitlist (transformed into care as usual at follow-up)
Number of subjects: 142
Study: 32928580

Group type: COMPARATOR
Intervention: Standard Care Group (SCG)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet Group (MDG)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Mediterranean Lifestyle Group (MLG)
Number of subjects: 180
Study: 32464878

Group type: EXPERIMENTAL
Intervention: Non-Ischemic Heart Preservation (NIHP)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Static Cold Storage (SCS)
Number of subjects: 37
Study: 33522342

Group type: EXPERIMENTAL
Intervention: Pravastatin (2 × 20 mg p.o) in addition to aspirin (80 mg p.o) and calcium (1 g p.o) from 14 to 20 weeks until delivery
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 33892830

Group type: EXPERIMENTAL
Intervention: Fluoride varnish applied biannually
Number of subjects: 5397

Group type: COMPARATOR
Intervention: Control group (no fluoride varnish)
Number of subjects: 5397
Study: 36052454

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT) for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 30
Study: 33825498

Group type: EXPERIMENTAL
Intervention: 2-mSv CT (n = 1535 patients)
Number of subjects: 3074

Group type: COMPARATOR
Intervention: Conventional-dose CT (CDCT) (n = 1539 patients)
Number of subjects: 3074
Study: 36004716

Group type: EXPERIMENTAL
Intervention: Probiotic Bacillus clausii UBBC‐07 (2×10^9 per 5 ml vial) taken daily twice for three months
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo suspension
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Probiotic Bacillus clausii UBBC‐07
Number of subjects: 90
Study: 33563473

Group type: EXPERIMENTAL
Intervention: Central venous pressure (CVP) monitoring
Number of subjects: 2029

Group type: EXPERIMENTAL
Intervention: Fluid administration during KT
Number of subjects: 2029
Study: 33883156

Group type: EXPERIMENTAL
Intervention: Food insecure households (newly or consistently)
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Consistent food insecurity
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Households changing from food secure to insecure
Number of subjects: 569
Study: 34610332

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy in combination with surgery
Number of subjects: 280

Group type: COMPARATOR
Intervention: Upfront surgery
Number of subjects: 280

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 280
Study: 34269087

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propensity score weighting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Full-interaction propensity model
Number of subjects: 0
Study: 32602373

Group type: EXPERIMENTAL
Intervention: Small needle-knife therapy (1 to 3 treatments over seven days)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Oral Celecoxib
Number of subjects: 83
Study: 34666553

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Causal Decision-Analytic Markov Model (CDAMM)
Number of subjects: 0
Study: 32870471

Group type: EXPERIMENTAL
Intervention: Once-weekly semaglutide 0.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Once-weekly dulaglutide 0.75 mg
Number of subjects: 0
Study: 35174541

Group type: EXPERIMENTAL
Intervention: Endo-wing-assisted colonoscopy (EAC)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Transparent hood-assisted colonoscopy (TAC)
Number of subjects: 800
Study: 33737200

Group type: EXPERIMENTAL
Intervention: Peer-delivered behavioral diabetes self-care program over the phone (6 months, 11 sessions)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Self-paced general health program
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Peer-delivered behavioral diabetes self-care program over the phone
Number of subjects: 403
Study: 33599688

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with carboplatin
Number of subjects: 634

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy without carboplatin
Number of subjects: 634
Study: 32357903

Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis of peer support intervention
Number of subjects: 558
Study: 33675133

Group type: EXPERIMENTAL
Intervention: Group 1 (no poor risk features; surveillance)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Group 2 (intermediate pathologic risk factors; 50-Gy radiotherapy)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Group 3 (poor prognostic pathologic factors; concurrent 56-Gy chemoradiotherapy with weekly cisplatin)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Locoregional failures (LRFs)
Number of subjects: 54
Study: 32396568

Group type: EXPERIMENTAL
Intervention: Psychological symptoms assessed using Brief Symptom Inventory (BSI) and Global Severity Index (GSI)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Post-traumatic stress symptoms assessed using Impact of Event Scale-Revised (IES-R)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Subjective quality of life assessed using Manchester Short Assessment of Quality of Life (MANSA)
Number of subjects: 130
Study: 35021171

Group type: EXPERIMENTAL
Intervention: Probiotic mouthrinse
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse (0.12%)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Sodium fluoride mouthrinse (0.05%)
Number of subjects: 51
Study: 35695362

Group type: EXPERIMENTAL
Intervention: Ultravist
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Visipaque
Number of subjects: 46
Study: 32822510

Group type: EXPERIMENTAL
Intervention: Forced Prolonged Position (FPP)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 221
Study: 33534333

Group type: EXPERIMENTAL
Intervention: T4H program (home helpers assisting older adults with exercise coaching using IT devices)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (standard home help)
Number of subjects: 35
Study: 32214062

Group type: EXPERIMENTAL
Intervention: Task-based mirror therapy (TBMT) for 25 minutes per day for 25 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Occupational therapy (control group) for 25 minutes per day for 25 days
Number of subjects: 30
Study: 34196380

Group type: EXPERIMENTAL
Intervention: auto-EPAP
Number of subjects: 50

Group type: COMPARATOR
Intervention: fixed-EPAP
Number of subjects: 50
Study: 33609104

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 16400

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 16400

Group type: EXPERIMENTAL
Intervention: White blood cell count
Number of subjects: 16400

Group type: EXPERIMENTAL
Intervention: Neutrophil count
Number of subjects: 16400

Group type: EXPERIMENTAL
Intervention: Monocyte count
Number of subjects: 16400

Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 16400

Group type: EXPERIMENTAL
Intervention: Interleukin-6
Number of subjects: 16400
Study: 36179066

Group type: EXPERIMENTAL
Intervention: UP165 (corn leaf extract) 250 mg/day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: UP165 (corn leaf extract) 500 mg/day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: UP165 (corn leaf extract)
Number of subjects: 45
Study: 32594774

Group type: EXPERIMENTAL
Intervention: Glittre-ADL test without the backpack
Number of subjects: 40

Group type: COMPARATOR
Intervention: Glittre-ADL test with the backpack
Number of subjects: 40
Study: 35162750

Group type: EXPERIMENTAL
Intervention: Multicomponent Aquatic Training (MAT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34237743

Group type: EXPERIMENTAL
Intervention: 3-day training on drinking and micturition habits
Number of subjects: 0
Study: 35389681

Group type: EXPERIMENTAL
Intervention: CAPS-5
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: PCL-5
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Both CAPS-5 and PCL-5
Number of subjects: 198
Study: 35301135

Group type: EXPERIMENTAL
Intervention: Electronic sleep positional therapy wearable device
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 100
Study: 35390172

Group type: EXPERIMENTAL
Intervention: MK‐1092 (4-64 nmol/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MK‐1092 (≥ 16 nmol/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MK‐1092
Number of subjects: 0
Study: 33121332

Group type: EXPERIMENTAL
Intervention: BPAUM score (body mass index, proteinuria, age, uric acid, mean arterial pressure)
Number of subjects: 907
Study: 32395836

Group type: EXPERIMENTAL
Intervention: Avatar education application
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 36
Study: 35522187

Group type: EXPERIMENTAL
Intervention: Microfluidic sperm preparation
Number of subjects: 386

Group type: COMPARATOR
Intervention: Density-gradient centrifugation (control)
Number of subjects: 386
Study: 33377568

Group type: EXPERIMENTAL
Intervention: High-flow
Number of subjects: 563

Group type: COMPARATOR
Intervention: Standard-oxygen
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: High-flow (in children with obstructive airway disease)
Number of subjects: 563

Group type: COMPARATOR
Intervention: Standard-oxygen (in children with obstructive airway disease)
Number of subjects: 563
Study: 33983785

Group type: EXPERIMENTAL
Intervention: ImPACT cognitive tests (current five-composite structure)
Number of subjects: 36091

Group type: EXPERIMENTAL
Intervention: Four-factor model identified through CFA
Number of subjects: 36091

Group type: EXPERIMENTAL
Intervention: Exploratory factor analysis (EFA)
Number of subjects: 36091
Study: 32221294

Group type: EXPERIMENTAL
Intervention: Anaerobutyricum soehngenii
Number of subjects: 24
Study: 35264154

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 33
Study: 33525925

Group type: EXPERIMENTAL
Intervention: Parasacral transcutaneous electrical nerve stimulation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham electrotherapy
Number of subjects: 40
Study: 32817311

Group type: EXPERIMENTAL
Intervention: Vitamin K2 400 μg oral supplementation once daily for a year
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 33438441

Group type: EXPERIMENTAL
Intervention: DESCANT intervention (personalised care package with memory aids and training)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Orientation clocks (91%), whiteboards (60%), calendars (43%), notebooks (32%)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: DESCANT intervention
Number of subjects: 128
Study: 34186138

Group type: EXPERIMENTAL
Intervention: Pilates training combined with biofeedback training
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Kegel training combined with biofeedback training
Number of subjects: 42

Group type: COMPARATOR
Intervention: Kegel training alone
Number of subjects: 42
Study: 32771433

Group type: EXPERIMENTAL
Intervention: Nasal mucosa graft
Number of subjects: 40

Group type: COMPARATOR
Intervention: Temporalis fascia graft
Number of subjects: 40
Study: 32683215

Group type: EXPERIMENTAL
Intervention: Hand Arm Bimanual Intensive Therapy (HABIT)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Constraint Induced Movement Therapy (CIMT)
Number of subjects: 16
Study: 32964537

Group type: EXPERIMENTAL
Intervention: Serelaxin treatment
Number of subjects: 6112

Group type: EXPERIMENTAL
Intervention: Diuretic responsiveness
Number of subjects: 6112

Group type: EXPERIMENTAL
Intervention: LVEF quartile Q4 (LVEF >50%)
Number of subjects: 6112

Group type: EXPERIMENTAL
Intervention: LVEF quartiles
Number of subjects: 6112

Group type: EXPERIMENTAL
Intervention: Patients in upper three LVEF quartiles with WRF
Number of subjects: 6112

Group type: COMPARATOR
Intervention: Patients in lowest LVEF quartile
Number of subjects: 6112
Study: 34710395

Group type: EXPERIMENTAL
Intervention: French‐contingent learning group (active sucking on a sensor‐equipped pacifier to infant‐directed French lullabies and readings)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Chinese‐contingent learning group (active sucking on a sensor‐equipped pacifier to infant‐directed Mandarin lullabies and readings)
Number of subjects: 41

Group type: COMPARATOR
Intervention: English‐enrichment control group (passive exposure to English infant‐directed lullabies and readings)
Number of subjects: 41
Study: 32968957

Group type: EXPERIMENTAL
Intervention: Gemcitabine monotherapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Non-gemcitabine arms
Number of subjects: 8
Study: 32570015

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 36209072

Group type: EXPERIMENTAL
Intervention: 1.0% phentolamine mesylate ophthalmic solution (PMOS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 34290573

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS) + optimal medical therapy (OMT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT)
Number of subjects: 29
Study: 36301512

Group type: EXPERIMENTAL
Intervention: Daily oral nonsteroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 2361

Group type: EXPERIMENTAL
Intervention: Subcutaneous tanezumab 2.5 mg (every 8 weeks)
Number of subjects: 2361

Group type: COMPARATOR
Intervention: NSAIDs and tanezumab
Number of subjects: 2361
Study: 34863458

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus carboplatin chemotherapy
Number of subjects: 93

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Cogstate composite score decline
Number of subjects: 93
Study: 33327786

Group type: EXPERIMENTAL
Intervention: 11 + S warm-up program performed at least three times a week for eight weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 28
Study: 33612630

Group type: EXPERIMENTAL
Intervention: Caromma biscuit (100 g/day for 4 weeks)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Temma biscuit (100 g/day for 4 weeks)
Number of subjects: 64
Study: 35881217

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided umbilical venous catheter insertion (US group)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard method of insertion (SD group)
Number of subjects: 53
Study: 32966845

Group type: EXPERIMENTAL
Intervention: Surgical interval (SI) of 6 weeks
Number of subjects: 3085

Group type: EXPERIMENTAL
Intervention: Lengthening of SI
Number of subjects: 3085

Group type: EXPERIMENTAL
Intervention: Radiotherapy dose
Number of subjects: 3085

Group type: EXPERIMENTAL
Intervention: Addition of oxaliplatin to Nad‐CRT
Number of subjects: 3085
Study: 35918028

Group type: EXPERIMENTAL
Intervention: Tiny Cargo, Big Deal!/Abróchame Bien, Cuídame Bien (TCBD/ABCB) intervention, which includes motivational interviewing and tailored eHealth components.
Number of subjects: 900

Group type: COMPARATOR
Intervention: Enhanced usual care (control group).
Number of subjects: 900
Study: 34195469

Group type: EXPERIMENTAL
Intervention: Socio-spiritual intervention consisting of four weekly face-to-face sessions focusing on spirituality, social support, and information needs
Number of subjects: 152

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 152
Study: 35242370

Group type: EXPERIMENTAL
Intervention: PLLA sternal pins (Group P)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group without PLLA sternal pins (Group N)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (Group P and Group N)
Number of subjects: 100
Study: 34048946

Group type: EXPERIMENTAL
Intervention: pembrolizumab
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: second-course pembrolizumab
Number of subjects: 1034

Group type: COMPARATOR
Intervention: docetaxel
Number of subjects: 1034
Study: 32909643

Group type: EXPERIMENTAL
Intervention: apremilast 30 mg b.i.d.
Number of subjects: 69
Study: 33044756

Group type: EXPERIMENTAL
Intervention: Ixekizumab every 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ixekizumab every 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33745731

Group type: EXPERIMENTAL
Intervention: PCV10 (2+1 schedule)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: PCV13 (2+1 schedule)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Unvaccinated controls
Number of subjects: 250
Study: 36351066

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection
Number of subjects: 54

Group type: COMPARATOR
Intervention: Other infectious pathogens
Number of subjects: 54
Study: 32554068

Group type: EXPERIMENTAL
Intervention: 10 J/cm2 laser protocol
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 30 J/cm2 laser protocol
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 57
Study: 35952621

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Motor Control (MC)
Number of subjects: 41
Study: 32122152

Group type: EXPERIMENTAL
Intervention: Walking programs, health newsletters, community leader trainings, teacher and student trainings, health integration into schools
Number of subjects: 239
Study: 33534750

Group type: EXPERIMENTAL
Intervention: Radio frequency‐induced heat therapy (RFHT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Handheld exothermic crystallization thermotherapy for CL (HECT‐CL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison of cure rates between RFHT and HECT-CL
Number of subjects: 40
Study: 32135414

Group type: EXPERIMENTAL
Intervention: Chumlea's formulas for the American black population (CBP)
Number of subjects: 1754

Group type: EXPERIMENTAL
Intervention: Chumlea's formulas for whites (CC)
Number of subjects: 1754

Group type: EXPERIMENTAL
Intervention: New proposed formula for height estimation
Number of subjects: 1754
Study: 34560903

Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention and/or omega-3 supplementation
Number of subjects: 1630
Study: 32975202

Group type: EXPERIMENTAL
Intervention: Rivaroxaban + Verapamil (n=30)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Rivaroxaban + Amlodipine (n=51)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (Rivaroxaban without CCBs, n=47)
Number of subjects: 128
Study: 34627853

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 158

Group type: COMPARATOR
Intervention: Dalteparin
Number of subjects: 158
Study: 33245791

Group type: EXPERIMENTAL
Intervention: En bloc transurethral resection (ERBT)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Conventional transurethral resection (cTURBT)
Number of subjects: 123
Study: 33378079

Group type: EXPERIMENTAL
Intervention: Implants without peri-implantitis
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Implants diagnosed with peri-implantitis
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Risk factors for buccal PISTD
Number of subjects: 240
Study: 36126864

Group type: EXPERIMENTAL
Intervention: HD-tDCS (F3, F4)
Number of subjects: 11

Group type: COMPARATOR
Intervention: SHAM
Number of subjects: 11
Study: 36370741

Group type: EXPERIMENTAL
Intervention: mDOT
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Patient Navigation
Number of subjects: 755
Study: 32957034

Group type: EXPERIMENTAL
Intervention: Single-dose patellar tendon isometric exercise protocol
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham-TENS protocol
Number of subjects: 28
Study: 35771546

Group type: EXPERIMENTAL
Intervention: Apatinib plus Pegylated Liposomal Doxorubicin (PLD)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Pegylated Liposomal Doxorubicin (PLD)
Number of subjects: 152
Study: 34377472

Group type: EXPERIMENTAL
Intervention: MagNOVOx™
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (inulin)
Number of subjects: 12
Study: 33385511

Group type: EXPERIMENTAL
Intervention: Ziziphus spinosa (ZS) 2 g daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 32462542

Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine (1 µg/kg during a 10-min infusion)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Subcutaneous dexmedetomidine (1 µg/kg during a 10-min infusion)
Number of subjects: 10
Study: 35536366

Group type: EXPERIMENTAL
Intervention: Modified Reverse Step-Cut Osteotomy (MRSO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Yun's Reverse V Osteotomy (RVO)
Number of subjects: 20
Study: 33964223

Group type: EXPERIMENTAL
Intervention: R21 plus 25 μg MM (Group 1)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: R21 plus 50 μg MM (Group 2)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Rabies vaccinations (Group 3, Control)
Number of subjects: 450
Study: 32291132

Group type: EXPERIMENTAL
Intervention: Manual segmentation method
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Semi-automated segmentation method
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Automated segmentation method
Number of subjects: 15
Study: 36343348

Group type: EXPERIMENTAL
Intervention: ENT‐01
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 33544883

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg (after switching from ETN)
Number of subjects: 677